Amgen (AMGN) Multiple Could Expand Post Sandoz Biosimilar Ruling - Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Evan Seigerman reiterated an Outperform rating and $202.00 price target on Amgen (NASDAQ: AMGN) after the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
